BRAF and thyroid gland carcinoma: Therapeutic approaches that use pharmacological inhibitors targeting tyrosine kinase receptors (TKIs), BRAF V600E, Mitogen-activated kinases, mTOR, anaplastic lymphoma kinase, tropomyosin receptor kinases are proposed to reduce radio- and chemoresistance of thyroid cancer (14).